Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
53,514,204
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
15,926,513
-
Shares change
-
-261,948
-
Total reported value, excl. options
-
$42,841,966
-
Value change
-
-$709,927
-
Number of buys
-
8
-
Number of sells
-
-7
-
Price
-
$2.69
Significant Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q4 2022
30 filings reported holding XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2022.
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15,926,513 shares
of 53,514,204 outstanding shares and own 30% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (2,805,413 shares), Atlas Venture Life Science Advisors, LLC (2,759,344 shares), Octagon Capital Advisors LP (2,425,000 shares), FMR LLC (1,907,671 shares), RiverVest Venture Management LLC (1,441,444 shares), Rock Springs Capital Management LP (1,362,878 shares), VANGUARD GROUP INC (890,353 shares), Artal Group S.A. (450,000 shares), HARVARD MANAGEMENT CO INC (416,059 shares), and Trustees of Columbia University in the City of New York (249,635 shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.